KathrynAnnGoldMD

Oncology • La Jolla, CA

Hematologic Oncology

Associate Professor, University of California San Diego

Join to view full profile

Dr. Gold is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gold's full profile

Already have an account?

Office
3855 Health Sciences Dr # 987
La Jolla, CA 92093
Phone+1 858-822-5182

Fax+1 858-822-6186

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2005 - 2008
Washington University in St. Louis School of MedicineClass of 2005

Certifications & Licensure

CA State Medical License 2015 - 2025
TX State Medical License 2008 - 2024
PA State Medical License 2005 - 2008
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2018 Jun 06
Active, not recruiting
Phase 1

Publications & Presentations

PubMed

172 citations
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Apar Kishor P Ganti, Billy W Loo, Michael Bassetti, Collin Blakely, Anne Chiang
Journal of the National Comprehensive Cancer Network. 2021-12-01
349 citations
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Martin Reck, Alexander Luft, Aleksandra Szczesna, Libor Havel, Sang We Kim
Journal of Clinical Oncology. 2016-07-25
395 citations
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
James Chih-Hsin Yang, Myung-Ju Ahn, Dong Wan Kim, Suresh S. Ramalingam, Lecia V. Sequist
Journal of Clinical Oncology. 2017-02-21

Press Mentions

COVID-19 Pandemic Is Driving up Rate of Late-Stage Cancer Diagnoses, UCSD Researchers SayFebruary 17th, 2022
COVID Pandemic Driving up Late-Stage Cancer Rates, UCSD FindsFebruary 15th, 2022
Increase in Late-Stage Cancer Diagnoses After PandemicFebruary 15th, 2022